Group items tagged

A Phase 3 study comparing Samsung Bioepis' SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).

A regimen of neoadjuvant Keytruda and chemotherapy extended pathological complete response (pCR) rates by 13.6% compared to chemotherapy alone in patients with early triple-negative breast cancer (TNBC), according to findings from the Phase III Keynote-522 study presented at the ESMO Congress 2019.

Digital health interventions (DHIs) are fast emerging as vital tools to promote personal health and provide essential services. DHIs can be accessed through mobile phones, tablets and computers, as well as serve as effective support systems to improve personal health.

Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.

Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.

ImmunoGen has presented full data from the Phase III Forward I study of mirvetuximab soravtansine in ovarian cancer at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, saying that it failed to meet the primary endpoint of progression-free survival (PFS).

Despite advances in the renal cell carcinoma (RCC) therapy landscape, the majority of patients with RCC will eventually develop resistance to available therapies and the disease will progress through several stages, requiring further lines of treatment.

Advances in cancer treatments, such as immunotherapies and precision medicines, have been associated with a corresponding rise in the cost of new and innovative medicines.

Immuno-Transcriptomics firm Novigenix has received positive results from its early colon cancer detection blood test at the European Society for Medical Oncology (ESMO) 2019.